Results 181 to 190 of about 161,329 (309)

Sperm Retrieval in Non-Azoospermic Patients with Intact Ejaculation: A Narrative Review. [PDF]

Int J Fertil Steril
Amir Jannati N, Akhavizadegan H, Kalantari H, Sabbaghian M, Sadighi Gilani MA.   +4 more
europepmc   +1 more source

Prevalence of Hypercementosis in Radiographic Studies: A Systematic Review and Meta‐Analysis With Clinical Implications for Endodontic Assessment

International Endodontic Journal, EarlyView.
ABSTRACT Background Hypercementosis is a non‐neoplastic condition characterized by excessive cementum deposition along the root surface, resulting in altered apical morphology. Although often asymptomatic and detected incidentally on radiographs, changes in apical contour may influence anatomical complexity in endodontic treatment.
Carlos Segura‐Raya, Víctor Diaz‐Flores, Milagros Martín‐Jiménez, Juan J. Segura‐Egea   +3 more
wiley   +1 more source

The diguanylate cyclase and phosphodiesterase locally regulate the virulence factors in Vibrio vulnificus. [PDF]

Gut Pathog
Yang JR, Chen KT, Chen YW, Lai SJ.
europepmc   +1 more source

Efficacy and Safety of Oral Icotrokinra in Moderate‐to‐Severe Plaque Psoriasis: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

International Journal of Dermatology, EarlyView.
Meta‐analysis of randomized controlled trials demonstrates that oral icotrokinra significantly improves PASI responses in patients with moderate‐to‐severe plaque psoriasis, with early clinical benefit and a placebo‐comparable safety profile, supported by trial sequential analysis confirming robust and sufficient evidence.
Alhasan Altayf, Munder Lateiresh, Lutfiyah Marwan, Mohamed Yaseen Alfeetouri, Yassine Zouaoui, Muhammed Elhadi   +5 more
wiley   +1 more source

Covalent Binding of the Boronic Acid-Based Inhibitor GSK4394835A to Phosphodiesterase 3B, a Drug Target for Cardiovascular Disease. [PDF]

J Med Chem
Eaton SA, Christianson DW.
europepmc   +1 more source

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Tadashi Terui, Yukari Okubo, Satomi Kobayashi, Akimichi Morita, Shinichi Imafuku, Yayoi Tada, Masatoshi Abe, Bruce Strober, Melinda Gooderham, Wendy Zhang, Junichiro Shimauchi, Masafumi Yaguchi, Takeshi Kimura, Ryuichi Ogawa, Hamid Amouzadeh, Masamoto Murakami   +15 more
wiley   +1 more source

Synthesis and Pharmacological Evaluation of 6,7-Dihydro‑3<i>H</i>‑Oxazolo[3,4‑<i>a</i>]Pyrazine-5,8-Dione Compounds as Inhibitors of Phosphodiesterases 4 and 5. [PDF]

ACS Med Chem Lett
Helfstein DR, das Virgens MF, Rojas Moscoso JA, Zaminelli T, Toledo FT, Maia de Lima J, Medeiros LO, Marcello BA, Soares VM, Passos GR, de Padua SS, Wolf MEG, Carneiro LM, De Nucci G, Keppler AF, Mónica FZ.   +15 more
europepmc   +1 more source

Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild‐to‐moderate psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Balinatunfib is the first oral, small molecule selective inhibitor of TNFR1 signaling. The results of this study indicate that balinatunfib treatment was tolerable with no serious or severe adverse events in patients with mild‐to‐moderate psoriasis and showed clinical responses.
Nassr Nassr, Ohn A. Chow, Mai Anh Nguyen, Laurent Perrin, Fabienne Schumacher, Frank‐Dietrich Wagner, Caroline Dreis, Amel Lahmar, Markus Kohlmann, Maria Wiekowski, Tiago R. Matos   +10 more
wiley   +1 more source

PDE4C stabilized by ELAVL1 promotes lymph node metastasis in papillary thyroid cancer. [PDF]

Am J Cancer Res
Cui T, Zhang Y, Li W, Zhang D, Liu W, Gong H.   +5 more
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source